Nutritional and Genetic Determinants of Hormone Levels in Relation to Prostate Cancer Risk

2001 ◽  
Vol 101 (s45) ◽  
pp. 14P-14P
Author(s):  
Naomi E. Allen
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Genetic Determinants ◽  
Hormone Levels

GENETIC DETERMINANTS OF PROSTATE CANCER RISK

2007 ◽  
Vol 100 (2) ◽  
pp. 241-243 ◽  
Author(s):  
Mark M. Pomerantz ◽  
Matthew L. Freedman ◽  
Philip W. Kantoff
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Genetic Determinants

scholarly journals Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk

2004 ◽  
Vol 7 (4) ◽  
pp. 333-337 ◽  
Author(s):  
H Kakinuma ◽  
N Tsuchiya ◽  
T Habuchi ◽  
C Ohyama ◽  
S Matsuura ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Steroid Hormone ◽  
Prostate Cancer Risk ◽  
Sex Steroid ◽  
Sex Steroid Hormone ◽  
Hormone Levels

scholarly journals A Large Study of Androgen Receptor Germline Variants and Their Relation to Sex Hormone Levels and Prostate Cancer Risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

2010 ◽  
Vol 95 (9) ◽  
pp. E121-E127 ◽  
Author(s):  
Sara Lindström ◽  
Jing Ma ◽  
David Altshuler ◽  
Edward Giovannucci ◽  
Elio Riboli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Sex Hormone ◽  
Cag Repeats ◽  
Sex Steroid ◽  
Sequence Variants ◽  
Hormone Levels ◽  
Breast And Prostate Cancer

Background: Androgens are key regulators of prostate gland maintenance and prostate cancer growth, and androgen deprivation therapy has been the mainstay of treatment for advanced prostate cancer for many years. A long-standing hypothesis has been that inherited variation in the androgen receptor (AR) gene plays a role in prostate cancer initiation. However, studies to date have been inconclusive and often suffered from small sample sizes. Objective and Methods: We investigated the association of AR sequence variants with circulating sex hormone levels and prostate cancer risk in 6058 prostate cancer cases and 6725 controls of Caucasian origin within the Breast and Prostate Cancer Cohort Consortium. We genotyped a highly polymorphic CAG microsatellite in exon 1 and six haplotype tagging single nucleotide polymorphisms and tested each genetic variant for association with prostate cancer risk and with sex steroid levels. Results: We observed no association between AR genetic variants and prostate cancer risk. However, there was a strong association between longer CAG repeats and higher levels of testosterone (P = 4.73 × 10−5) and estradiol (P = 0.0002), although the amount of variance explained was small (0.4 and 0.7%, respectively). Conclusions: This study is the largest to date investigating AR sequence variants, sex steroid levels, and prostate cancer risk. Although we observed no association between AR sequence variants and prostate cancer risk, our results support earlier findings of a relation between the number of CAG repeats and circulating levels of testosterone and estradiol.

5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia

2006 ◽  
Vol 120 (4) ◽  
pp. 776-780 ◽  
Author(s):  
Vanessa M. Hayes ◽  
Gianluca Severi ◽  
Emma J.D. Padilla ◽  
Howard A. Morris ◽  
Wayne D. Tilley ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Androgenetic Alopecia ◽  
Gene Variant ◽  
Hormone Levels
Sign in / Sign up

Export Citation Format

Share Document